Immix Biopharma, Inc. logo

Immix Biopharma, Inc.

NASDAQ:IMMX

Overview | Financials
Company Name Immix Biopharma, Inc.
Symbol IMMX
Currency USD
Price 2.18
Market Cap 59,966,649
Dividend Yield 0%
52-week-range 1.26 - 7.46
Industry Biotechnology
Sector Healthcare
CEO Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
Website https://www.immixbio.com

An error occurred while fetching data.

About Immix Biopharma, Inc.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for

Related Stocks

Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc.

AVTX

8.81 USD

FSD Pharma Inc. logo

FSD Pharma Inc.

HUGE

0.09 USD

T2 Biosystems, Inc. logo

T2 Biosystems, Inc.

TTOO

0.345 USD

ARCA biopharma, Inc. logo

ARCA biopharma, Inc.

ABIO

28.8 USD

Financials

Numbers are in millions USD

Numbers are in millions USD